medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-7-68-71medsovet-215Research ArticleНЕФРОЛОГИЯNEPHROLOGYСулодексид. Нефропротективные свойства и горизонты применения в нефрологииSulodexide. Nephroprotective properties and horizons for use in nephrologyБатюшинМ. М.BatyushinM. M.noemail@neicon.ruРостовский государственный медицинский университет Минздрава РоссииРоссияRostov State Medical University, Russia's Ministry of HealthRussian Federation201530122015076871Copyright © Батюшин М.М., 20152015Батюшин М.М.Batyushin M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/215

Сулодексид относится к классу препаратов гликозаминогликанов (ГАГ) или мукополисахаридов. ГАГ обнаруживаются в тканях млекопитающих и регулируют активность целого ряда белков (хемокины, цитокины, факторы роста, ферменты, морфогены, молекулы адгезии). ГАГ представляют собой длинные линейные, обычно сульфатированные отрицательно заряженные полисахариды с молекулярной массой от 1 до 2 000 кДа. Они организованы в виде повторяющихся дисахаридных фрагментов уроновых кислот (D-глюкуроновой и L-идуроновой кислоты) и ацетилированного аминосахарида (N-ацетилгалактозамин и N-ацетилглюкозамин), сульфатированного или несульфатированного [5]. Зона сульфатирования ГАГ вариабельна и зависит от локализации на клетке или в ткани. ГАГ существуют в составе протеогликанов, а также в свободном виде. К несульфатированным ГАГ относится гиалуроновая кислота, к сульфатирован-ным - хондроитин сульфат, дерматан сульфат, кератан сульфат, гепарин и гепаран сульфат.

Sulodexide belongs to the class of glycosaminoglycans (GAGs) or mucopolysaccharides. Found in mammalian tissuesm, GAGs regulate the activity of a wide range of proteins (including chemokines, cytokines, growth factors, enzymes, morphogens, and adhesion molecules). GAGs are large, linear, frequently sulfated, negatively charged polysaccharides with a molecular weight ranging 1-2,000 kDa. They are organized as repetitions of disaccharide units of an uronic acid (D-glucuronic acid or L-iduronic acid) and an acetylated amino sugar (N-acetylgalactosamine or N-acetylglucosamine) either sulfated or non-sulfated. [5] The position of sulfation of GAGs is widely variable depending on their cell and tissue localization. GAGs exist both as part of proteoglycans and as free chains. Non-sulfated GAGs include hyaluronic acid and sulfated GAGs include chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, and heparan sulfate.

сулодексидгепараназа-1 протеинуриядиабетическая нефропатияsulodexideheparanase-1proteinuriadiabetic nephropathyReferencesБатюшин М.М., Галушкин А.А., Литвинов А.С. и соавт. Место сулодексида в ренопротективной терапии больных с хронической болезнью почек. Медицинский вестник Юга России. 2012; 1: 72-73.Батюшин М.М., Галушкин А.А., Литвинов А.С. и соавт. Место сулодексида в ренопротективной терапии больных с хронической болезнью почек. Медицинский вестник Юга России. 2012; 1: 72-73.Батюшин М.М., Галушкин А.А., Асрумян Э.Г. и соавт. Сулодексид - новые перспективы в нефропротективной терапии. Клиническая нефрология. 2012; 3: 56-61.Батюшин М.М., Галушкин А.А., Асрумян Э.Г. и соавт. Сулодексид - новые перспективы в нефропротективной терапии. Клиническая нефрология. 2012; 3: 56-61.Батюшин М.М., Пасечник Д.Г. Выявление виментина, панцитокератина, гладкомышеч-ного актина, е-катгерина и антител к CD-10 -маркеров эпителиально-мезенхимального перехода при хроническом гломерулонефрите. Нефрология. 2014; 5: 52-58.Батюшин М.М., Пасечник Д.Г. Выявление виментина, панцитокератина, гладкомышеч-ного актина, е-катгерина и антител к CD-10 -маркеров эпителиально-мезенхимального перехода при хроническом гломерулонефрите. Нефрология. 2014; 5: 52-58.ALicic RZ, TuttLe KR. Novel Therapies for Diabetic Kidney Disease. Advances in Chronic Kidney Disease. 2014; 21(2): 121-133.ALicic RZ, TuttLe KR. Novel Therapies for Diabetic Kidney Disease. Advances in Chronic Kidney Disease. 2014; 21(2): 121-133.Coccheri S, ManneLLo F. Development and use of suLodexide in vascuLar diseases: impLications for treatment. Drug Design, Development and Therapy. 2014; 8: 49-65.Coccheri S, ManneLLo F. Development and use of suLodexide in vascuLar diseases: impLications for treatment. Drug Design, Development and Therapy. 2014; 8: 49-65.Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y et aL. Loss of heparin suLfate gLycosaminogLy-can assembLy in podocytes does not Lead to proteinuria. Kidney Int. 2008; 74(3): 289-299.Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y et aL. Loss of heparin suLfate gLycosaminogLy-can assembLy in podocytes does not Lead to proteinuria. Kidney Int. 2008; 74(3): 289-299.Wijnhoven TJ, Lensen JF, Rops AL et aL. Anti-proteinuric effects of gLycosaminogLycan-based drugs. Curr Opin Mol Ther. 2007; 9(4): 364-377.Wijnhoven TJ, Lensen JF, Rops AL et aL. Anti-proteinuric effects of gLycosaminogLycan-based drugs. Curr Opin Mol Ther. 2007; 9(4): 364-377.CeLie JW, Reijmers RM, SLot EM et aL. TubuLointerstitiaL heparan suLfate proteogLycan changes in human renaL diseases correLate with Leukocyte infLux and proteinuria. Am J Physiol Renal Physiol. 2008; 294(1): 253-263.CeLie JW, Reijmers RM, SLot EM et aL. TubuLointerstitiaL heparan suLfate proteogLycan changes in human renaL diseases correLate with Leukocyte infLux and proteinuria. Am J Physiol Renal Physiol. 2008; 294(1): 253-263.Benck U, HaeckeL S, CLorius JH, van der Woude FJ. Proteinuria- Lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aLdosterone system. Clin J Am Soc Nephrol. 2007; 2(1): 58-67.Benck U, HaeckeL S, CLorius JH, van der Woude FJ. Proteinuria- Lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aLdosterone system. Clin J Am Soc Nephrol. 2007; 2(1): 58-67.Ruggeri A, Guizzardi S, Franchi M et aL. Pharmacokinetics and distribution of a fLuores-ceinated gLycosaminogLycan, suLodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung. 1985; 35(10): 1517-1519.Ruggeri A, Guizzardi S, Franchi M et aL. Pharmacokinetics and distribution of a fLuores-ceinated gLycosaminogLycan, suLodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung. 1985; 35(10): 1517-1519.Lewis EJ, Xu X. AbnormaL gLomeruLar permeabiLity characteristics in diabetic nephropathy: impLications for the therapeutic use of Low-moLecuLar weight heparin. Diabetes Care. 2008; 31 SuppL 2: S202-S207.Lewis EJ, Xu X. AbnormaL gLomeruLar permeabiLity characteristics in diabetic nephropathy: impLications for the therapeutic use of Low-moLecuLar weight heparin. Diabetes Care. 2008; 31 SuppL 2: S202-S207.Gouverneur M, Broekhuizen L, Meuwese M et aL. SuLfated gLycosaminogLycans restore gLyco-caLyx barrier properties of cuLtured endotheLiaL ceLLs in hypergLycemia. FASEB J. 2008; 22: Lb83.Gouverneur M, Broekhuizen L, Meuwese M et aL. SuLfated gLycosaminogLycans restore gLyco-caLyx barrier properties of cuLtured endotheLiaL ceLLs in hypergLycemia. FASEB J. 2008; 22: Lb83.Karon J, Potubinska A, Antoniewicz AA. et aL. Anti-infLammatory effect of suLodexide during acute peritonitis in rats. Blood Purif. 2007; 25(5-6): 510-514.Karon J, Potubinska A, Antoniewicz AA. et aL. Anti-infLammatory effect of suLodexide during acute peritonitis in rats. Blood Purif. 2007; 25(5-6): 510-514.Ciszewicz M, PoLubinska A, Antoniewicz A. et aL. SuLodexide suppresses infLammation in human endotheLiaL ceLLs and prevents gLucose cytotox-icity. Transl Res. 2009; 153(3): 118-123.Ciszewicz M, PoLubinska A, Antoniewicz A. et aL. SuLodexide suppresses infLammation in human endotheLiaL ceLLs and prevents gLucose cytotox-icity. Transl Res. 2009; 153(3): 118-123.Shestakova M.V., Chugunova L.A., Vorontsov A.V., Dedov I.I. The efficacy of suLodexide - a Low-moLecuLar heparin - in the therapy of diabetic nephropathy. Ter Arkh. 1997; 69(6): 34-37.Shestakova M.V., Chugunova L.A., Vorontsov A.V., Dedov I.I. The efficacy of suLodexide - a Low-moLecuLar heparin - in the therapy of diabetic nephropathy. Ter Arkh. 1997; 69(6): 34-37.SzeLachowska M., PopLawska A., TopoLska J. et aL. A piLot study of the effect of the gLycosami-nogLycan suLodexide on microaLbuminuria in type I diabetic patients. Curr Med Res Opin. 1997; 13(9): 539-545.SzeLachowska M., PopLawska A., TopoLska J. et aL. A piLot study of the effect of the gLycosami-nogLycan suLodexide on microaLbuminuria in type I diabetic patients. Curr Med Res Opin. 1997; 13(9): 539-545.Sorrenti G., GrimaLdi M., Canova N. et aL. GLycosaminogLycans as a possibLe tooL for micro- and macroaLbuminuria in diabetic patients. A piLot study. J Int Med Res. 1997; 25(2): 81-86.Sorrenti G., GrimaLdi M., Canova N. et aL. GLycosaminogLycans as a possibLe tooL for micro- and macroaLbuminuria in diabetic patients. A piLot study. J Int Med Res. 1997; 25(2): 81-86.SoLini A., Vergnani L., Ricci F., CrepaLdi G. GLycosaminogLycans deLay the progression of nephropathy in NIDDM. Diabetes Care. 1997; 20(5): 819-823.SoLini A., Vergnani L., Ricci F., CrepaLdi G. GLycosaminogLycans deLay the progression of nephropathy in NIDDM. Diabetes Care. 1997; 20(5): 819-823.Dedov I., Shestakova M., Vorontzov A., PaLazzini E. A randomized, controLLed study of suLodexide therapy for the treatment of diabetic nephrop-athy. NephroL DiaL TranspLant. 1997; 12(11): 2295-2300.Dedov I., Shestakova M., Vorontzov A., PaLazzini E. A randomized, controLLed study of suLodexide therapy for the treatment of diabetic nephrop-athy. NephroL DiaL TranspLant. 1997; 12(11): 2295-2300.Gambaro G., KinaLska I., Oksa A. et aL. OraL suLo-dexide reduces aLbuminuria in microaLbuminu-ric and macroaLbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized triaL. J Am Soc NephroL. 2002; 13: 1615-1625.Gambaro G., KinaLska I., Oksa A. et aL. OraL suLo-dexide reduces aLbuminuria in microaLbuminu-ric and macroaLbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized triaL. J Am Soc NephroL. 2002; 13: 1615-1625.Heerspink H.L., Greene T., Lewis J.B. et aL. CoLLaborative Study Group. Effects of suLodex-ide in patients with type 2 diabetes and persistent aLbuminuria. NephroL DiaL TranspLant. 2008; 23(6): 1946-1954.Heerspink H.L., Greene T., Lewis J.B. et aL. CoLLaborative Study Group. Effects of suLodex-ide in patients with type 2 diabetes and persistent aLbuminuria. NephroL DiaL TranspLant. 2008; 23(6): 1946-1954.Achour A., Kacem M., Dibej K. et aL. One year course of oraL suLodexide in the management of diabetic nephropathy. J NephroL. 2005; 18(5): 568-574.Achour A., Kacem M., Dibej K. et aL. One year course of oraL suLodexide in the management of diabetic nephropathy. J NephroL. 2005; 18(5): 568-574.SuLikowska B., OLejniczak H., Muszynska M. et aL. Effect of suLodexide on aLbuminuria, NAG excretion and gLomeruLar fiLtration response to dopamine in diabetic patients. Am J NephroL. 2006; 26(6): 621-628.SuLikowska B., OLejniczak H., Muszynska M. et aL. Effect of suLodexide on aLbuminuria, NAG excretion and gLomeruLar fiLtration response to dopamine in diabetic patients. Am J NephroL. 2006; 26(6): 621-628.

The authors declare that there are no conflicts of interest present.